Dual Tyrosyl-DNA Phosphodiesterase/Topoisomerase Inibitors

Back to all technologies
Download as PDF
66149
Topoisomerase 1 (TOP1) is an enzyme involved in the replication of DNA. Molecules displaying TOP1 inhibitory function have found clinical applications as well as the frequent subject of research. Another enzyme functioning alongside TOP1 is tyrosyl-DNA phosphodiesterase 1 (TDP1), which repairs DNA lesions. Observations of this enzyme suggest mediating its activity could potentiate the cytotoxic effect of TOP1 inhibitors. TDP1 inhibitory activity has been seen to a limited extent in a handful of compounds, though their potencies, specificities, and pharmacokinetic properties leave much to be desired.

Purdue University researchers have developed a series of novel, low molecular-weight compounds that can act as dual inhibitors of both TOP1 and TDP1. A dual inhibitor of this type would offer significant advantages over individual TOP1 and TDP1inhibitors alone such as simplification of delivery and bioavailability. In lab tests, the dual inhibitor is an equally potent TOP1 inhibitor as the commercially available camptothecin. These molecules are thought to function by stalling the DNA synthesis phase of the cell cycle, thereby inducing apoptosis, and effectively killing the cell. This drug could work in combination with other chemotherapies to effectively eliminate highly proliferative cell growth in the body.

Advantages:
-First dual inhibitor of TOP1 and TDP1
-Shown to be as cytotoxic to TOP1 as camptothecin
-A potentially more potent chemotherapy agent

Potential Applications:
-Medical/Healthcare
-Pharmaceuticals
-Cancer Treatment
Sep 29, 2015
CON-Patent
United States
9,402,842
Aug 2, 2016

Nov 10, 2014
DIV-Patent
United States
9,175,002
Nov 3, 2015

Mar 15, 2013
Utility Patent
United States
8,912,213
Dec 16, 2014

Apr 13, 2012
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org